Role of Dadimadi Avaleha in treatment of Sickle cell anaemia
Phase 2
- Conditions
- Health Condition 1: D573- Sickle-cell trait
- Registration Number
- CTRI/2020/01/022912
- Lead Sponsor
- Department of Kaumarbhritya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Age between 3yrs to 16 yrs irrespective of gender.
2 Hb >6.5% and <11.5%.
3 Pre diagnosed cases will be taken.
4 Patients with positive sickling test.
5 Patients with sign and symptoms of Sickle cell Anaemia like pallor, fatique, pain, loss of appetite etc.
Exclusion Criteria
1 Age less than 3yrs and greater than 16 yrs.
2 Hb <6.5% and >11.5%.
3 SCA associated with other disease like Diabetes Mellitus, Hypertension, Thalassemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dadimadi Avaleha is effective as palliative care of Sickle cell anaemia in childrenTimepoint: 2 months
- Secondary Outcome Measures
Name Time Method Effect of Dadimadi Avaleha is more than or as effective as folic acid as palliative care of Sickle cell anaemia in childrenTimepoint: 2 months